Published Technical Disclosure Archive

Synergistic Gene Expression Systems for Rod Photoreceptors

Publication ID: 24-11857642_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Gene Expression Systems for Rod Photoreceptors,” Published Technical Disclosure No. 24-11857642_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857642_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,642.

Summary of the Inventive Concept

The present invention integrates the SYNP161 promoter with distinct technologies such as AI, IoT, blockchain, and new materials to create novel systems for targeted gene expression in rod photoreceptors, offering improved precision, efficiency, and personalized treatment options.

Background and Problem Solved

The original patent disclosed the SYNP161 promoter for gene expression in rod photoreceptors, but it had limitations in terms of regulation, precision, and scalability. The new inventive concept addresses these limitations by incorporating synergistic combinations of technologies to create more powerful and adaptable systems.

Detailed Description of the Inventive Concept

The inventive concept comprises a nucleic acid sequence of at least 150 base pairs and having at least 95% identity to the sequence of SEQ ID NO:1, operably linked to a gene encoding for a protein of interest. This sequence is integrated with an AI-powered gene regulation module for optimizing gene expression in response to environmental stimuli, a blockchain technology for secure data management, an IoT-enabled sensor for real-time monitoring, or a biocompatible material for ocular implants. The system enables targeted gene expression in rod photoreceptors, allowing for personalized gene therapy, gene editing, and machine learning-driven predictions of gene expression patterns.

Novelty and Inventive Step

The new claims introduce a synergistic combination of the SYNP161 promoter with distinct technologies, providing a novel and non-obvious solution for targeted gene expression in rod photoreceptors. The integration of AI, IoT, blockchain, and new materials with the promoter sequence enables a more efficient, precise, and adaptable system that was not anticipated by the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include variations in the AI-powered gene regulation module, such as using different machine learning algorithms or incorporating additional data sources. The IoT-enabled sensor could be replaced with other monitoring systems, and the biocompatible material could be modified for use in different implantable devices. These variations would ensure broad conceptual coverage and adaptability to different applications.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the fields of gene therapy, gene editing, and ocular implants. The integration of AI, IoT, blockchain, and new materials could lead to more efficient and personalized treatment options, addressing a significant market need in the field of ophthalmology.

CPC Classifications

SectionClassGroup
A A61 A61K48/0058
A A61 A61K48/00
C C12 C12N15/63
C C12 C12N15/79
C C12 C12N15/86
C C12 C12N2750/14143
C C12 C12N2830/008

Field of Art

Molecular biology, genetic engineering, and gene expression systems, specifically focused on promoter sequences and targeted gene delivery in photoreceptor cells

Person of Ordinary Skill (PHOSITA) Profile

A molecular biologist with expertise in genetic engineering, promoter analysis, vector design, and gene therapy techniques, holding a PhD or equivalent advanced degree with 3-5 years of specialized research experience in gene expression systems

Obviousness Rationale

A person of ordinary skill would recognize that integrating emerging technologies like AI, blockchain, and IoT with established gene expression systems represents a predictable extension of known techniques in molecular biology. The core promoter sequence remains substantially unchanged, with the primary innovation being the application of computational and monitoring technologies to enhance gene expression precision. These technological integrations would be considered routine optimization strategies by a skilled practitioner in the field.

Obvious Combinations & Variations

Source Patent Element
SYNP161 promoter sequence for rod photoreceptor gene expression
PTD Variation
AI-powered gene regulation module for optimizing expression in response to environmental stimuli
Obviousness Reasoning
Computational modulation of gene expression is a known technique, and applying machine learning to optimize promoter activity would be a predictable application of existing bioinformatics approaches
Source Patent Element
Expression cassette with nucleic acid sequence
PTD Variation
Blockchain technology for secure data management of gene therapy outcomes
Obviousness Reasoning
Secure data management is a standard requirement in medical technologies, and applying blockchain to genetic research represents an obvious technological integration
Source Patent Element
Vector-based gene delivery system
PTD Variation
IoT-enabled sensor for real-time monitoring of gene expression
Obviousness Reasoning
Continuous monitoring of biological processes is a well-established research technique, and integrating IoT sensors represents a straightforward technological enhancement
Source Patent Element
Gene expression in rod photoreceptor cells
PTD Variation
Biocompatible material incorporating promoter sequence for ocular implants
Obviousness Reasoning
Material science adaptations for biological interfaces are routine in biomedical engineering, and incorporating genetic sequences into implantable materials is a predictable design choice
Source Patent Element
Nucleic acid sequence for gene expression
PTD Variation
Machine learning model for predicting gene expression patterns
Obviousness Reasoning
Computational prediction of biological behaviors is a standard approach in systems biology, and developing predictive models from experimental data represents an obvious scientific progression
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this publication would be considered obvious to a person having ordinary skill in the art at the time of invention, when viewed in light of US Patent 11857642. The technological integrations represent predictable combinations of known techniques in molecular biology, genetic engineering, and computational systems, thereby rendering potential claims of novelty invalid as obvious extensions of prior art.

Original Patent Information

Patent NumberUS 11,857,642
TitleSYNP161, a promoter for the expression of genes
Assignee(s)FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH